Literature DB >> 28883900

Corrigendum to "Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E2 Receptor EP4 Pathway".

Yu Ah Hong1, Keum Jin Yang2, So Young Jung2, Ki Cheol Park2, Hyunsu Choi2, Jeong Min Oh2, Sang Ju Lee1, Yoon Kyung Chang1, Cheol WheePark1, Chul Woo Yang1, Suk Young Kim1, Hyeon Seok Hwang1.   

Abstract

[This corrects the article DOI: 10.1155/2017/5031926.].

Entities:  

Year:  2017        PMID： 28883900      PMCID： PMC5572087          DOI： 10.1155/2017/1913954

Source DB:  PubMed          Journal:  Oxid Med Cell Longev        ISSN： 1942-0994            Impact factor:   6.543


In the article titled “Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E2 Receptor EP4 Pathway” [1], an acknowledgement should be added as follows: The authors also wish to acknowledge the financial support of the Korean Society of Nephrology (JW Pharmaceutical, 2013).
  1 in total

1.  Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E2 Receptor EP4 Pathway.

Authors:  Yu Ah Hong; Keum Jin Yang; So Young Jung; Ki Cheol Park; Hyunsu Choi; Jeong Min Oh; Sang Ju Lee; Yoon Kyung Chang; Cheol Whee Park; Chul Woo Yang; Suk Young Kim; Hyeon Seok Hwang
Journal:  Oxid Med Cell Longev       Date:  2017-03-29       Impact factor: 6.543
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.